365 related articles for article (PubMed ID: 12678140)
1. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy.
Pongnikorn S; Fongmoon D; Kasinrerk W; Limtrakul PN
J Med Assoc Thai; 2003 Jan; 86(1):61-8. PubMed ID: 12678140
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract.
Limtrakul P; Khantamat O; Pintha K
Cancer Chemother Pharmacol; 2004 Dec; 54(6):525-30. PubMed ID: 15248030
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic activity in lymphocytes from radiation-treated cervical cancer patients.
Sueblinvong T; Pamutha P
J Med Assoc Thai; 2003 Feb; 86(2):157-65. PubMed ID: 12678154
[TBL] [Abstract][Full Text] [Related]
4. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
5. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
Inayat-ur-Rahman ; Malik SA; Bashir M; Khan R; Iqbal M
Phytomedicine; 2009 May; 16(5):401-5. PubMed ID: 19362455
[TBL] [Abstract][Full Text] [Related]
6. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats.
Shih CC; Lin CH; Lin WL; Wu JB
J Ethnopharmacol; 2009 May; 123(1):82-90. PubMed ID: 19429344
[TBL] [Abstract][Full Text] [Related]
7. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer.
Cosiski Marana HR; Santana da Silva J; Moreira de Andrade J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):318-23. PubMed ID: 10985887
[TBL] [Abstract][Full Text] [Related]
8. [Short term therapeutic effect on treatment of postoperational large intestine carcinoma by Fupiyiwei decoction combined with chemotherapy and it's effect on immune function].
Wu G; Yu G; Li J; Xiong F
Zhongguo Zhong Yao Za Zhi; 2010 Mar; 35(6):782-5. PubMed ID: 20545209
[TBL] [Abstract][Full Text] [Related]
9. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients.
Balch CM; Tilden AB; Dougherty PA; Cloud GA; Abo T
Surgery; 1984 Jan; 95(1):63-70. PubMed ID: 6581546
[TBL] [Abstract][Full Text] [Related]
11. Changes in natural killer cell activity by external radiotherapy and/or brachytherapy.
Yamazaki H; Yoshioka Y; Inoue T; Tanaka E; Nishikubo M; Sato T; Ishida T; Nakamura H; Inoue T
Oncol Rep; 2002; 9(2):359-63. PubMed ID: 11836608
[TBL] [Abstract][Full Text] [Related]
12. Simple enumerations of peripheral blood natural killer (CD56+ NK) cells, B cells and T cells have no predictive value in IVF treatment outcome.
Thum MY; Bhaskaran S; Bansal AS; Shehata H; Ford B; Sumar N; Abdalla HI
Hum Reprod; 2005 May; 20(5):1272-6. PubMed ID: 15829490
[TBL] [Abstract][Full Text] [Related]
13. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
14. [Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice].
Zhou AG; Zhang Y; Kui G; Kong DY; Ge HL; Ren QH; Dong JR; Hong S; Mao XM; Wang Y; Zhang HZ; Wang SJ
Zhong Xi Yi Jie He Xue Bao; 2008 Jan; 6(1):77-82. PubMed ID: 18184551
[TBL] [Abstract][Full Text] [Related]
15. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
16. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
17. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
18. Increased natural killer cell activity in uterine cervix cancer patients undergoing radiation therapy.
Pinel MI; Esteves EB; Rumjanek VM
Nat Immun; 1995 Apr; 14(4):216-24. PubMed ID: 8696011
[TBL] [Abstract][Full Text] [Related]
19. [Effect of Xiaochaihu decoction and different herbal formulation of component on inhibiting H22 liver cancer in mice and enhancing immune function].
Li J; Xie M; Gan Y
Zhongguo Zhong Yao Za Zhi; 2008 May; 33(9):1039-44. PubMed ID: 18652353
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy-induced changes of peripheral blood lymphocyte subpopulations in cervical cancer patients: relationship to clinical response.
Eric A; Juranic Z; Tisma N; Plesinac V; Borojevic N; Jovanovic D; Milovanovic Z; Gavrilovic D; Ilic B
J BUON; 2009; 14(1):79-83. PubMed ID: 19373951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
